Christina A. Brezing, MD is an Assistant Professor of Psychiatry in the Division on Substance Use Disorders at Columbia University Irving Medical Center where she studies medication development for substance use disorders through clinical trials and applications of technology in the assessment and treatment of substance use disorders. She is Principal Investigator of two NIDA-funded grants including a K23 to study novel pharmacotherapy and applications of technology in the treatment of Cannabis Use Disorder and a R21 to study the comparative effectiveness of telehealth for buprenorphine treatment of Opioid Use Disorder at Columbia’s Substance Treatment and Research Services (STARS) program. She was recently awarded the Columbia University Vagelos College of Physicians, Doris Duke Charitable Foundation COVID-19 Fund to Retain Clinical Scientists that will support her research to understand the effects of testosterone replacement therapy on androgen deficiency in men with Opioid Use Disorder receiving early buprenorphine treatment. She was a Columbia Hadar Fellow and has received research support through the Columbia Smither’s Foundation and the Dartmouth Center for Technology and Behavioral Health. She has served as a co-investigator or study physician on dozens of NIDA-funded medication treatment trials for substance use disorders. She is the director of the addiction curriculum for the Columbia psychiatry residency and co-director of the American Academy of Addiction Psychiatry’s Advanced Addiction Psychopharmacology course.Dr. Brezing attended Duke University for her undergraduate degree in biology with a focus in biochemistry, and completed her medical degree at the University of Florida where she graduated Alpha Omega Alpha and with honors in research. She completed the Howard Hughes Medical Institute-National Institutes of Health (HHMI-NIH) Research Scholars Program studying neuroimaging of impulse control disorders, including pathological gambling, compulsive sexual behavior, and shopping. She completed psychiatry residency at Harvard Medical School-Massachusetts General Hospital and McLean Hospital, where she served as chief resident in addiction, in addition to a National Institute on Drug Abuse (NIDA) funded T32 research fellowship in Addiction Psychiatry at Columbia University and New York State Psychiatric Institute.